Recently published research powered by GNS Healthcare, maker of a causal machine-learning platform for precision medicine, promises to unravel some of the mysteries of Parkinson’s disease, specifically the rate of progression of the neurodegenerative condition.
Being able to use these [novel] predictors in the clinical setting will lead to faster and significantly cheaper clinical trials and accelerate the availability of new Parkinson’s Disease drugs for patients in need.
Read the full article from Neil Versel at GenomeWeb here.